Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I Interferonopathy

23 Jan 2019

Abstract excerpt

Aicardi-Goutières syndrome (AGS) is a rare, juvenile-onset autoinflammatory disease characterized by basal ganglia calcification, chronic cerebrospinal fluid (CSF) lymphocytosis, and elevated type I interferon (IFN) levels in the CSF 1, 2. Typical clinical manifestations include developmental delay, intellectual impairment, chilblains, panniculitis, glaucoma, and autoimmunity overlapping with systemic lupus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Inflammasome and immune disorders
Share to interferon and immune responses
Share to Systemic Lupus Erythematosus Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30666809
DOI: 10.1002/art.40805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi‐Goutières Syndrome, a Type I InterferonopathyPMID 30666809Read ↗

Baricitinib Treatment in RNU7-1-Associated Aicardi-Goutières Syndrome in a South African Child: A Case Report.Semantic proximity Read ↗

Type I Interferonopathies in Childhood.Semantic proximity Read ↗

Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome.Semantic proximity Read ↗

Aicardi-Goutières syndrome: A monogenic type I interferonopathy.Semantic proximity Read ↗

Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defectSemantic proximity Read ↗

Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report.Semantic proximity Read ↗

Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defect.Semantic proximity Read ↗

The prototypical interferonopathy: Aicardi-Goutières syndrome from bedside to bench.Semantic proximity Read ↗

Analysis of clinical characteristics of children with Aicardi-Goutieres syndrome in China.Semantic proximity Read ↗

Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity.Semantic proximity Read ↗

Aicardi-Goutières Syndrome caused by SAMHD1 mutation: Pathogenesis and Beyond.Semantic proximity Read ↗

Treatments in Aicardi–Goutières syndromeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.